Combined Antimuscarinics for Treatment of Neurogenic Overactive Bladder

International Journal of Immunopathology and Pharmacology

Volumn 25, Issue , 2012, Pages 35-41

  Nardulli, R ^a   Losavio, E ^a   Ranieri, M ^b   Fiore, P ^c   Megna, G ^b   Bellomo, R G ^d   Cristella, G ^e   Megna, M ^b  

^a Spinal Unit Cassano Murge (Ba)   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e Osmairm Neuropsychomotor Rehabilitation Center Laterza (Ta)   (Italy)

Author keywords

antimuscarinic; neurogenic bladder; spinal cord injury

Indexed keywords

OXYBUTYNIN; SOLIFENACIN; TROSPIUM CHLORIDE; BENZILIC ACID DERIVATIVE; MANDELIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTROPANE DERIVATIVE; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER CONTRACTION; BLURRED VISION; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTERMITTENT CATHETERIZATION; MALE; MICTURITION; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD INJURY; URGE INCONTINENCE; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; PATHOPHYSIOLOGY;

ADULT; BENZILATES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; NORTROPANES; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84878894429     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/03946320120250S106     Document Type: Article

References (29)

1. Bladder Management for Adults With Spinal Cord Injury. The Journal of Spinal Cord Medicine 2006; Vol 29 Number 5: 527-573
2. Blaivas JG, Barbalias GA,. Detrusor external sphincter dyssynergia in men with multiple sclerosis: An ominous urologic condition. J Urol 1984; 131: 91-94.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurol Urodyn 2002; 21: 167-68
4. Samson G, Cardenas D,. Neurogenic Bladder in Spinal Cord Injury. Phys Med Rehabil Clin N Am 2007; 18: 255-274
5. Hesch K,. Agents for treatment of overactive bladder: A therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 307-314. 4
6. Braverman AS, Luthin GR, Ruggieri MR,. M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol. 1998; 275: R1654-R1660.
7. Milani R, Scalambrino S, Milia R,. Double-blind cross-over cmparison of flavoxate and oxybutynin in women affected by urinary urge syndrome. Int Urogynecol J 1993; 4: 3-8
8. Appell RA,. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997; 50: 90-96
9. Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, Sparf B,. Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207
10. Hedge S,. Muscarinic receptors in the bladder. British Journal of Pharmacology 2006; 147, S80-S87
11. Amend B, et al. Effective Treatment of Neurogenic Detrusor Dysfunction by Combined High-Dosed Antimuscarinics without Increased Side-Effects. European Urology 2008; 53: 1021-1028
12. Morgan DM, McGuire EJ,: Managing bladder disorders in patients with spinal cord injury. Contemp Urol 2004; Feb: 12-26.
13. Fowler CJ,: Neurological disorders of micturition and their treatment. Brain 1999; 122: 1213-31
14. Frankel HL, Coll JR, Charlifue SW, et al. Long-term survival in spinal cord injury: A fifty year investigation. Spinal Cord 1998; 36: 266-74
15. DeVivo MJ, Krause JS, Lammertse DP,: Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 1999; 80: 1411-9
16. Chancellor MB, Anderson RU, Bone TB,: Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 2006; 85: 536-545
17. Bennett N, O'Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171: 749-51
18. Andersson KE, Yoshida M,: Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 2003; 43: 1-5
19. Burgard EC, Bookout AL, McKenna DG, et al. Modulation of calcium currents in bladder sensory neurons by antimuscarinic agents. Abstract. Presented at: The American Urological Association Annual Meeting; May 21-26, 2005; San Antonio, Texas; Abstract no. 151
20. Yamanishi T., Chappie C.R., Chess-Williams R., Which muscarinic receptor is important in the bladder? World J Urol 2001; 19: 299-306
21. Hegde SS, Mammen M, Jasper JR,. Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies. Curr Opin Invest Drugs 2004; 5: 40-9
22. Staskin DR, MacDiarmid SA,. Using anticholinergics to treat overactive bladder: The issue of treatment tolerability. Am J Med 2006; 119: 9-15.
23. Chappie CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D,. The effects of antimuscarinics treatment in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-562
24. Yarker YE, Goa KL, Fitton A,: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62
25. Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000; 95: 718-21
26. Anderson RU, Mobley D, Blank B, et al. Once-daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999; 161: 1809-12
27. Madersbacher H,. Oral anticholinergics in overactive bladder. Urologe A 2006; 45: 830-4.
28. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492: 243-50
29. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97-103